Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes

References

• Bray MS, Boerwinkle E, Doris PA. (2001). High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat 17:296–304
   PubMed Web of Science ®Google Scholar
• Chen L, Qin S, Xie J, et al. (2008). Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9:691–702
   PubMed Web of Science ®Google Scholar
• Clendenen TV, Rendleman J, Ge W, et al. (2015). Genotyping of Single Nucleotide Polymorphisms in DNA Isolated from Serum Using Sequenom MassARRAY Technology. PLoS One 10:e0135943
   PubMed Web of Science ®Google Scholar
• Crettol S, Venetz JP, Fontana M, et al. (2008). CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 30:689–99
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, Flockhart DA. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–58
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. (2008). Revised definitions of Invasive Fungal Diseases from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycoses Study Group (EORTC/MSG) Consensus Group[J]. Clin Infect Dis 12:1813–21
   Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Chen SC, et al. (2012). Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 56:4793–9
   PubMed Web of Science ®Google Scholar
• Dote S, Sawai M, Nozaki A, et al. (2016). A retrospective analysis of patient-specific factors on voriconazole clearance. J Pharm Health Care Sci. 19 2:10
   PubMed Web of Science ®Google Scholar
• Encalada Ventura MA, van Wanrooy MJ, Span LF, et al. (2016). Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrob Agents Chemother 60:2727–31
   PubMed Web of Science ®Google Scholar
• FDA Antiviral Drugs Advisory Committee.Briefing document for voriconazole (oral and intravenous formulations). (2001). Available at http://www.fda.gov/ohrms/dockets/AC/01/briefing/3792b2_01_Pfizer.pdf, 10-04
   Google Scholar
• Guery BP, Arendrup MC, Auzinger G, et al. (2009). Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 35:55–62
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Fonrose X, Tonini J, et al. (2015). Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother 59:2305–14
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. (2003). Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540–7
   PubMed Web of Science ®Google Scholar
• Hamada Y, Seto Y, Yago K, et al. (2012). Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 18:501–7
   PubMed Web of Science ®Google Scholar
• Hope WW, Castagnola E, Groll AH, et al. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18 Suppl 7:38–52
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Duettmann W, Raggam RB, et al. (2013). Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 57:3262–7
   PubMed Web of Science ®Google Scholar
• He HR, Sun JY, Ren XD, et al. (2015). Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis 34:811–19
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. (2003). Voriconazole. Clin Ther 25:1321–81
   PubMed Web of Science ®Google Scholar
• Jin H, Wang T, Falcione BA, et al. (2016). Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother 71:1772–85
   PubMed Web of Science ®Google Scholar
• Kriengkauykiat J, Ito JI, Dadwal SS. (2011). Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 3:175–91
   PubMedGoogle Scholar
• Lamoureux F, Duflot T, Woillard JB, et al. (2016). Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents 47:124–31
   PubMed Web of Science ®Google Scholar
• Lee CR, Goldstein JA, Pieper JA. (2002). Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–63
   PubMedGoogle Scholar
• Lee S, Kim BH, Nam WS, et al. (2012). Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 52:195–203
   PubMed Web of Science ®Google Scholar
• Lortholary O, Petrikkos G, Akova M, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 18 Suppl 7:68–77
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A, Glrard T, Farndon P, et al. (2010). Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69:222–30
   PubMed Web of Science ®Google Scholar
• Limper AH, Knox KS, Sarosi GA, et al. (2011). An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128
   PubMed Web of Science ®Google Scholar
• Mizutani T. (2003). PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35:99–106
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. (2005). Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–5
   PubMed Web of Science ®Google Scholar
• Murayama N, Imai N, Nakane T, et al. (2007). Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti fungal agent, in human liver microsomes. Biochem Pharmacol 15 73:2020–6
   PubMed Web of Science ®Google Scholar
• Miyakis S, van Hal SJ, Ray J, et al. (2010). Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 16:927–33
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, et al. (2002). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–53
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. (2004). Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:4419–31
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. (2008). Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 15 46:201–11
   PubMed Web of Science ®Google Scholar
• Pascual A, Csajka C, Buclin T, et al. (2012). Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55:381–90
   PubMed Web of Science ®Google Scholar
• Shi YY, He L. (2005). Shesis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97–8
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker AC, Debiasi RM, et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–51
   PubMed Web of Science ®Google Scholar
• Trembizki E, Smith H, Lahra MM, et al. (2014). High-throughput informative single nucleotide polymorphism-based typing of Neisseria gonorrhoeae using the Sequenom MassARRAY iPLEX platform. J Antimicrob Chemother 69:1526–32
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation(HCT). Clin Microbiol Infect 18 Suppl 7:53–67
   PubMed Web of Science ®Google Scholar
• Wang G, Lei HP, Li Z, et al. (2009). The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 65:281–5
   PubMed Web of Science ®Google Scholar
• Wang T, Chen S, Sun J, et al. (2014). Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother 69:463–70
   PubMed Web of Science ®Google Scholar
• Weigel JD, Hunfeld NG, Koch BC, et al. (2015). Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Intensive Care Med 41:2013–14
   PubMed Web of Science ®Google Scholar
• Weiss J, Ten Hoevel MM, Burhenne J, et al. (2009). CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 49:196–204
   PubMed Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, et al. (2014). Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis 15209:1941–8
   PubMed Web of Science ®Google Scholar